Immunotherapy for Dog Allergy Cost: Protocol-Tier Breakdown

This page is about subcutaneous allergen immunotherapy (SCIT) administered to HUMAN patients whose IgE is sensitized to dog allergens. Veterinary allergen-specific immunotherapy (vASIT) is a different product prescribed by veterinarians to treat the dog's own atopic dermatitis — typically injected into the dog at $30–$80 per vial by brands including Heska, Spectrum, and ALK-Abelló Veterinary. Human SCIT for dog allergy is prescribed by board-certified human allergists, billed under CPT codes 95115, 95117, 95165, and 95004 to the human patient's health insurance, and follows the Cox 2011 Practice Parameter Third Update protocol (CMS LCD L36240). These are entirely separate treatment categories, separate billing pathways, and separate insurance systems.

The Cox 2011 Practice Parameter Third Update (JACI 2011;127[1 Suppl]:S1-S55) describes three build-up protocol tiers. Conventional build-up involves one injection per week for 24–28 weeks (~26 total build-up visits), then 13 early maintenance visits for a Year 1 total of ~39 visits; patient cost at $20 copay = ~$780 in Year 1 copays. Cluster build-up condenses the schedule to 8–10 clinic visits with 2–3 injections per session (30-minute observation between each); same CPT codes but fewer total trips — however, same-day E/M billing in cluster protocols frequently triggers modifier-25 audits. Rush build-up (CPT 95180 rapid desensitization) compresses build-up to a single day or two-day escalation; 2025 Medicare allowed for 95180 is $135.90/hr; prior authorization is routinely required across commercial carriers for rush protocols. All three protocols share the same maintenance phase (~14 visits/year for 3–5 years) and the same CPT 95117/95165 codes for ongoing injections.

Can f 5 is prostatic kallikrein, produced exclusively in the prostate glands of intact male dogs — not in female dogs or neutered males. Approximately 16.5% of dog-sensitized adults are monosensitized to Can f 5 (Ozuygur Ermis et al., Allergy 2023). In a randomized double-blind placebo-controlled challenge, Schoos et al. (JACI Pract 2020) found that all 7 Can f 5-monosensitized children tolerated female dog extract with zero reaction. For these patients, the most cost-effective 'protocol' is no immunotherapy at all: adopting a female or neutered male dog removes the primary allergen source. Additionally, Can f 5 is frequently absent from commercial dog SCIT extracts — meaning patients who are Can f 5-sensitized and proceed with SCIT without component-resolved pre-testing may be paying for a protocol that does not target their actual sensitizing protein.

CPT 95180 is billed for rapid allergen desensitization (rush or ultra-rush protocols) when a patient receives escalating doses of allergen extract in a single-day or two-day intensive session rather than over 24–28 weekly visits. The 2025 Medicare-allowed rate is $135.90 per hour. Rush protocols are rarely used for dog SCIT specifically because the evidence base for dog SCIT is already described as 'poor and conflicting' in the 2016 Ann Allergy, Asthma and Immunology systematic review — adding the additional cost and prior-authorization complexity of rush desensitization is rarely justifiable. Commercial payers (BCBS, Aetna, UHC, Cigna, Anthem) typically require prior authorization for 95180, adding 5–15 business days of processing time. If approved, rush build-up eliminates the 26 weekly clinic visits of conventional build-up but does not reduce the maintenance phase or the 3–5 year treatment duration.

A hospital outpatient department (HOPD) adds a facility fee to the professional service fee, multiplying the total bill 4–40× compared to a freestanding allergist office. The structural lesson from the Geisinger Scenery Park case is that corporate ownership does not predict billing classification: Geisinger was acquired by Risant Health (Kaiser Permanente's non-profit subsidiary) in 2024, yet the Scenery Park site generated a $1,711 patient-owed amount for a routine allergy test because it is classified as an HOPD (Sze Wing Yu / WPSU Public Radio, March 24, 2026). Kaiser-owned sites in Southern California charge $0 for allergy injections under the same Risant parent. For dog immunotherapy patients, the most protective action is asking the billing department directly: 'Is this practice classified as a hospital outpatient department?' and requesting the expected facility fee in writing before any testing or injection appointment.

Yes, indirectly. A 2016 systematic review in Annals of Allergy, Asthma and Immunology examined 17 clinical trials of dog allergen immunotherapy and concluded results showed 'poor and conflicting results of clinical efficacy, attributed to poor-quality extracts and the inherent complex allergenic profile of dogs that remains without a clearly dominant allergen.' Unlike cat SCIT — which has FDA-standardized extracts at 10,000 BAU/mL and positive randomized controlled trials (Alvarez-Cuesta 1994 JACI; Varney 1997 Clin Exp Allergy; Lent 2006 JACI) — dog SCIT has neither standardized extracts nor a consistently positive RCT record. The CPT billing amounts are identical regardless of allergen species, but the cost-effectiveness argument for a 3–5 year dog SCIT protocol is structurally weaker than for cat SCIT because the underlying evidence is less robust.

Timing significantly affects out-of-pocket cost for patients with high-deductible health plans (HDHPs). HDHP deductibles reset January 1 each year. A patient who starts SCIT build-up in January will burn through their deductible within the first 2–3 visits (skin testing plus first vial preparation typically generates $400–$1,200 in allowed amounts), then pay only coinsurance or copays for the remainder of the year. A patient who starts in October or November hits the deductible in the fall, then has the deductible reset before they reach the less expensive post-deductible phase — effectively paying full allowed amounts twice across two calendar years. For conventional build-up (26 weekly visits over 6 months), starting in January is the most cost-protective timing. For cluster or rush build-up, the compressed timeline reduces this concern but does not eliminate it.